Epidermal powder immunization using non-toxic bacterial enterotoxin adjuvants with influenza vaccine augments protective immunity
D Chen, RL Endres, CA Erickson, YF Maa, LG Payne - Vaccine, 2002 - Elsevier
D Chen, RL Endres, CA Erickson, YF Maa, LG Payne
Vaccine, 2002•ElsevierThe non-toxic B subunit of cholera toxin (CTB) and E. coli heat-labile toxin mutant proteins
with reduced toxicity (LTR72) or no toxicity (LTK63) were used as adjuvants for epidermal
powder immunization (EPI) with an influenza vaccine. When administered by EPI, CTB,
LTR72 and LTK63 significantly augmented antibody responses to the influenza vaccine and
protection against a lethal challenge in a mouse model. The antigen dose could be reduced
by 125-fold. These adjuvants were well-tolerated both locally and systemically following EPI …
with reduced toxicity (LTR72) or no toxicity (LTK63) were used as adjuvants for epidermal
powder immunization (EPI) with an influenza vaccine. When administered by EPI, CTB,
LTR72 and LTK63 significantly augmented antibody responses to the influenza vaccine and
protection against a lethal challenge in a mouse model. The antigen dose could be reduced
by 125-fold. These adjuvants were well-tolerated both locally and systemically following EPI …
The non-toxic B subunit of cholera toxin (CTB) and E. coli heat-labile toxin mutant proteins with reduced toxicity (LTR72) or no toxicity (LTK63) were used as adjuvants for epidermal powder immunization (EPI) with an influenza vaccine. When administered by EPI, CTB, LTR72 and LTK63 significantly augmented antibody responses to the influenza vaccine and protection against a lethal challenge in a mouse model. The antigen dose could be reduced by 125-fold. These adjuvants were well-tolerated both locally and systemically following EPI. These results suggest that EPI with influenza vaccine and a non-toxic bacterial enterotoxin hold promise for human vaccination.
Elsevier